Pancreatic cancer drug arrives with a $39,800 monthly price, but costs depend on coverage and aid

FDA approves Revolution Medicines’ oral daraxonrasib (Rasonque) for metastatic pancreatic adenocarcinoma after phase 3 results showing a 60% reduction in death risk and median survival of 13.2 months versus 6.7 with chemotherapy. The wholesale list price is about $39,800 for a 30‑day supply (roughly $477,000/year), but patients’ out‑of‑pocket costs vary with insurance; Medicare Part D and discounts can reduce costs by about 20–30%, and aid programs (e.g., Path) may offer low or zero copays for eligible patients. Side effects include rash, diarrhea, mucositis, nausea, fatigue, and edema. The drug is not a cure but offers a life‑extending option for a historically hard‑to‑treat cancer; about 67,000 pancreatic cancer diagnoses are expected in 2026.